BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Авг. 5, 2024
The
effect
of
nirmatrelvir/ritonavir
on
preventing
post-COVID
condition
(PCC)
in
the
BA4,
BA5,
and
XBB
Omicron
predominant
periods
is
not
well
understood.
purpose
this
study
was
to
assess
how
treatment
affected
both
PCC
health-related
quality
life.
This
retrospective
cohort
enrolled
2,524
adults
aged
18
years
older
who
were
eligible
for
between
July
14
November
14,
2022.
All
outcomes
observed
from
patient's
first
visit
primary
health
clinic,
1
week,
month,
3
months,
6
months
after
testing
positive
COVID-19.
outcome
presence
PCC.
Secondary
included
effects
life,
such
as
walking,
bathing
dressing,
activities,
cause
adverse
emotions
or
signs
that
prevent
individuals
leading
normal
lives
over
a
180-day
observation
period.
There
no
significant
differences
those
administered
(control
group)
terms
symptoms
at
(OR
0.71
95%
CI
0.31,
1.64)
1.30
0.76,
2.21).
At
use
associated
with
26%
reduction
causing
negative
0.74
0.60,
0.92)
an
increased
likelihood
limiting
walking
1.58
1.10,
2.27).
However,
there
control
group
impact
life
months.
Our
indicates
administration
does
significantly
reduce
population
high
vaccination
coverage.
Journal of Clinical Medicine,
Год журнала:
2023,
Номер
12(23), С. 7375 - 7375
Опубликована: Ноя. 28, 2023
Antiviral
treatment
reduces
the
severity
and
mortality
of
SARS-CoV-2
infection;
however,
its
effectiveness
against
long
COVID-19
is
unclear.
This
study
aimed
to
evaluate
antiviral
drugs
in
preventing
COVID
related
hospitalizations/deaths.
Scientific
medical
databases
were
searched
from
1
January
2020
30
June
2023.
We
included
observational
cohort
studies
comparing
individuals
receiving
early
therapy
for
those
supportive
treatment.
A
fixed-effects
model
was
used
merge
effects
reported
two
or
more
studies.
The
risk
post-acute
sequelae
(PASC)
combined
as
an
odds
ratio
(OR).
Six
selected,
including
a
total
3,352,235
participants.
occurrence
PASC
27.5%
lower
patients
who
received
during
stages
infection
(OR
=
0.725;
95%
confidence
interval
[CI]
0.409–0.747)
than
group.
Moreover,
PASC-associated
hospitalization
29.7%
group
0.721;
CI
0.697–0.794).
Early
associated
with
reduced
death.
Thus,
recommended
at-risk
individuals.
Expert Opinion on Pharmacotherapy,
Год журнала:
2023,
Номер
24(17), С. 1839 - 1843
Опубликована: Сен. 21, 2023
On
31
July
2023,
the
United
States
Department
of
Health
and
Human
Services
announced
formation
Office
Long
COVID
Research
Practice
National
Institutes
opened
enrollment
for
RECOVER-Vital,
a
randomized
study
to
evaluate
new
treatment
options
long
Coronavirus
(long
COVID).The
RECOVER
Initiative
is
$1.15
billion
research
platform
intended
describe,
categorize,
treat,
prevent
long-term
symptoms
following
infection
by
Severe
Acute
Respiratory
Syndrome
2
(SARS‑CoV‑2),
virus
that
causes
(COVID-19).
More
than
200
have
been
associated
with
COVID,
potentially
affecting
nearly
all
body
systems,
current
estimates
suggest
between
7
million
23
Americans
developed
COVID.
However,
there
are
no
approved
treatments
this
condition.The
first
prospective,
initiative,
will
SARS-CoV-2
antiviral
nirmatrelvir/ritonavir
(Paxlovid)
as
potential
This
manuscript
explores
what
known
about
Paxlovid
treat
examines
rationale
addressing
condition
an
agent.
Frontiers in Psychiatry,
Год журнала:
2025,
Номер
16
Опубликована: Март 21, 2025
Background
Given
that
atrial
fibrillation
(AF)
s
associated
with
a
high
risk
of
psychiatric
disorders,
understanding
the
potential
benefits
catheter
ablation
is
clinically
significant.
This
study
was
conducted
to
examine
whether
can
prevent
disorders
in
patients
AF.
Methods
A
retrospective
cohort
over
two
years
using
data
from
TriNetX
electronic
health
record
network.
The
included
adults
diagnosed
AF
and
treated
either
antiarrhythmic
or
rate-control
medications.
Participants
were
divided
into
groups:
those
who
underwent
control
group
without
ablation.
primary
outcome
measured
composite
anxiety,
depression,
insomnia
occurrence
within
one
three
post-treatment.
Secondary
outcomes
individual
suicidal
ideation
attempts,
dementia,
cerebral
infarction,
atopic
dermatitis
(as
negative
control).
Results
We
21,019
each
matched
group.
demonstrated
lower
combined
(hazard
ratio(HR):0.873,
95%
confidence
interval
(CI)
0.784–0.973,
p<0.01),
secondary
including
anxiety
(HR:0.822,
CI:0.700–0.964;
p=0.016),
depression
(HR:0.614,
CI:0.508–0.743;
p<0.001),
attempts
(HR:0.392,
CI:0.165–0.934;
p=0.028),
dementia
(HR:0.569,
CI:0.422–0.767;
infarction
(HR:0.704,
CI:0.622–0.797;
p<0.001)
compared
non-ablation
Conclusions
In
fibrillation,
reduced
developing
insomnia,
attempt,
comparison
did
not
undergo
Clinicians
should
consider
incorporating
factors
their
comprehensive
patient
assessment
when
evaluating
candidates
for
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 4, 2025
Abstract
IMPORTANCE
Nirmatrelvir-ritonavir,
an
efficacious
treatment
for
acute
COVID-19,
has
yielded
conflicting
evidence
regarding
its
effectiveness
in
preventing
Long
COVID
among
adults.
The
of
nirmatrelvir-ritonavir
adolescents
real-world
settings
is
not
well
understood.
OBJECTIVE
To
evaluate
the
aged
12
to
20
years
given
within
first
five
days
COVID-19
illness
on
severity
during
(days
0
27)
and
post-acute
phases
28
179).
DESIGN,
SETTING,
AND
PARTICIPANTS
This
target
trial
emulation
used
electronic
health
records
(EHR)
data
from
twenty-nine
medical
institutions
participating
NIH’s
RECOVER
consortium.
We
included
collected
between
April
1,
2022
December
31,
2023,
all
patients
with
a
SARS-CoV-2
infection
who
were
hospitalized
day
entry.
Those
treated
oral
5
after
positive
test
(n=2,923)
those
did
received
phase
(control
group,
n=31,947)
identified.
EXPOSURES
Treatment
based
prescription
records.
MAIN
OUTCOMES
MEASURES
modified
Poisson
regression
models
binary
outcomes
examine
effects
hospitalization,
emergency
department
(ED)
visits,
outpatient
visits
as
progression
moderate
or
severe
individuals
compared
control
counterparts.
Additionally,
we
assessed
medication’s
associations
16
conditions
symptoms
subsequent
association
specific
diagnostic
code
U09.9
phase.
reported
absolute
risks
estimated
relative
(RRs),
adjustments
made
demographic
variables,
clinical
characteristics,
healthcare
utilization,
using
propensity
score
matching.
RESULTS
study
cohort
34,870
(median
[Q1,
Q3]
age
16.0
[14.0,
18.0]);
46.0%
male
43.2%
Non-Hispanic
White.
Among
these
patients,
2,923
entry
31,947
no
treatment.
rates
0.58%
vs.
0.96%
74.17%
82.66%
1.81%
2.28%
ED
3.08%
3.99%
moderate/severe
illness,
0.21%
0.20%
long
diagnosis
group.
After
matching,
acute-phase
period,
was
associated
reduced
risk
any
hospitalization
(relative
(RR)
0.48;
95%
confidence
interval
(CI)
0.29-0.80),
visit
(RR
0.86;
CI
0.82-0.90),
0.69;
0.56-0.87).
7
specified
chest
pain
0.41;
0.26-0.63),
fatigue
malaise
0.49;
0.32-0.76),
generalized
0.65;
0.45-0.95),
headache
0.60;
0.44-0.83),
mental
0.56;
0.39-0.80),
musculoskeletal
0.63,
0.43-0.94),
respiratory
signs
0.61,
0.52-0.71).
No
found
suggest
that
0.96,
0.40-2.32).
CONCLUSIONS
RELEVANCE
infection,
utilization.
However,
lower
diagnosis.
Key
Points
Question
Does
reduce
developing
years?
Findings
In
this
day,
exhibited
including
symptoms,
observed
study.
Meaning
adolescents,
appears
be
effective
at
reducing
but
COVID.
